Brain Tumor Reports
54


Volume 18 Number 2
February 2016




Home > Publications > Brain Tumor Reports > Volume 18, Year 2016 > Number 2, February*




CONTENTS



BRAIN TUMORS
EMBRYONAL TUMORS
GLIOBLASTOMA
GLIOMAS
MEDULLOBLASTOMA





BRAIN TUMORS



Capilla-Gonzalez V, Bonsu JM, Redmond KJ, Garcia-Verdugo JM, Quiñones-Hinojosa A.
Implications of irradiating the subventricular zone stem cell niche.
Stem Cell Res. 2016 Mar;16(2):387-96. doi: 10.1016/j.scr.2016.02.031. Epub 2016 Feb 17.
Source | Abstract | Full text | Similar articles




PDQ Adult Treatment Editorial Board.
Adult Central Nervous System Tumors Treatment (PDQ®): Health Professional Version.
PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-2016 Jan 27.
Source | Abstract | Full text



EMBRYONAL TUMORS



PDQ Pediatric Treatment Editorial Board.
Childhood Central Nervous System Embryonal Tumors Treatment (PDQ®): Patient Version.
PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-2016 Jan 28.
Source | Abstract | Full text



GLIOBLASTOMA



Ansstas G, Tran DD.
Treatment with Tumor-Treating Fields Therapy and Pulse Dose Bevacizumab in Patients with Bevacizumab-Refractory Recurrent Glioblastoma: A Case Series.
Case Rep Neurol. 2016 Jan 8;8(1):1-9. doi: 10.1159/000442196. eCollection 2016 Jan-Apr.
Source | Abstract | Full text | Similar articles




Balana C, De Las Penas R, Sepúlveda JM, Gil-Gil MJ, Luque R, Gallego O, Carrato C, Sanz C, Reynes G, Herrero A, Ramirez JL, Pérez-Segura P, Berrocal A, Vieitez JM, Garcia A, Vazquez-Estevez S, Peralta S, Fernandez I, Henriquez I, Martinez-Garcia M, De la Cruz JJ, Capellades J, Giner P, Villà S.
Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial.
J Neurooncol. 2016 May;127(3):569-79. doi: 10.1007/s11060-016-2065-5. Epub 2016 Feb 3.
Source | Abstract | Full text | Similar articles




Brandes AA, Bartolotti M, Tosoni A, Poggi R, Bartolini S, Paccapelo A, Bacci A, Ghimenton C, Pession A, Bortolotti C, Zucchelli M, Galzio R, Talacchi A, Volpin L, Marucci G, de Biase D, Pizzolitto S, Danieli D, Ermani M, Franceschi E.
Patient outcomes following second surgery for recurrent glioblastoma.
Future Oncol. 2016 Apr;12(8):1039-44. doi: 10.2217/fon.16.9. Epub 2016 Feb 16.
Source | Abstract | Full text | Similar articles




Brandes AA, Carpentier AF, Kesari S, Sepulveda-Sanchez JM, Wheeler HR, Chinot O, Cher L, Steinbach JP, Capper D, Specenier P, Rodon J, Cleverly A, Smith C, Gueorguieva I, Miles C, Guba SC, Desaiah D, Lahn MM, Wick W.
A phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma.
Neuro Oncol. 2016 Feb 21. pii: now009. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



*

Jungk C, Chatziaslanidou D, Ahmadi R, Capper D, Bermejo JL, Exner J, von Deimling A, Herold-Mende C, Unterberg A.
Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naïve patients.
BMC Cancer. 2016 Feb 10;16:81. doi: 10.1186/s12885-016-2131-6.
Source | Abstract | Full text | Similar articles



**

Kruser TJ, Mehta MP, Kozak KR.
Identification of Patients Who Benefit From Bevacizumab in High-Grade Glioma-An Easy Question Turned Difficult: Treat the Scan or the Patient?
J Clin Oncol. 2016 Apr 10;34(11):1281-2. doi: 10.1200/JCO.2015.64.7883. Epub 2016 Feb 16.
Source | Abstract | Full text | Similar articles



*

Redjal N, Reinshagen C, Le A, Walcott BP, McDonnell E, Dietrich J, Nahed BV.
Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide.
J Neurooncol. 2016 May;127(3):505-14. doi: 10.1007/s11060-016-2054-8. Epub 2016 Feb 1.
Source | Abstract | Full text | Similar articles



**

Seystahl K, Wick W, Weller M.
Therapeutic options in recurrent glioblastoma--An update.
Crit Rev Oncol Hematol. 2016 Mar;99:389-408. doi: 10.1016/j.critrevonc.2016.01.018. Epub 2016 Jan 21.
Source | Abstract | Full text | Similar articles




Steffens R, Semrau S, Lahmer G, Putz F, Lettmaier S, Eyüpoglu I, Buchfelder M, Fietkau R.
Recurrent glioblastoma: who receives tumor specific treatment and how often?
J Neurooncol. 2016 May;128(1):85-92. doi: 10.1007/s11060-016-2079-z. Epub 2016 Feb 23.
Source | Abstract | Full text | Similar articles




Vogelbaum MA.
The benefit of surgical resection in recurrent glioblastoma.
Neuro Oncol. 2016 Apr;18(4):462-3. doi: 10.1093/neuonc/now004. Epub 2016 Feb 10.
Source | Abstract | Full text | Similar articles



GLIOMAS



Purow B.
For glioma, a sweet side to diabetes.
Neuro Oncol. 2016 Mar;18(3):306-7. doi: 10.1093/neuonc/nov328.
Source | Abstract | Full text | Similar articles




Wheeler LA, Manzanera AG, Bell SD, Cavaliere R, McGregor JM, Grecula JC, Newton HB, Lo SS, Badie B, Portnow J, Teh BS, Trask TW, Baskin DS, New PZ, Aguilar LK, Aguilar-Cordova E, Chiocca EA.
Phase 2 multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma.
Neuro Oncol. 2016 Feb 2. pii: now002. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



MEDULLOBLASTOMA



Galvis L, Gonzalez D, Bonilla C.
Relapsed High-Risk Medulloblastoma: Stable Disease after Two Years of Treatment with Somatostatin Analog - Case Report.
Cureus. 2016 Jan 4;8(1):e446. doi: 10.7759/cureus.446.
Source | Abstract | Full text | Similar articles




Grosshans DR.
Proton therapy for paediatric medulloblastoma.
Lancet Oncol. 2016 Mar;17(3):258-9. doi: 10.1016/S1470-2045(15)00217-X. Epub 2016 Jan 30.
Source | Abstract | Full text | Similar articles




Koschmann C, Bloom K, Upadhyaya S, Geyer JR, Leary SE.
Survival After Relapse of Medulloblastoma.
J Pediatr Hematol Oncol. 2016 May;38(4):269-73. doi: 10.1097/MPH.0000000000000547.
Source | Abstract | Meeting abstract | Similar articles




Vivekanandan S, Breene R, Ramanujachar R, Traunecker H, Pizer B, Gaze MN, Saran F, Thorp N, English M, Wheeler K, Michalski A, Walker DA, Saunders D, Cowie F, Cameron A, Picton S, Parashar D, Horan G, Williams MV.
Reply to Comment on: The UK Experience of a Treatment Strategy for Pediatric Metastatic Medulloblastoma Comprising Intensive Induction Chemotherapy, Hyperfractionated Accelerated Radiotherapy, and Response-Directed High-Dose Myeloablative Chemotherapy or Maintenance Chemotherapy (Milan Strategy).
Pediatr Blood Cancer. 2016 Jun;63(6):1125-6. doi: 10.1002/pbc.25946. Epub 2016 Feb 17.
Source | Abstract | Full text | Similar articles




Yock TI, Yeap BY, Ebb DH, Weyman E, Eaton BR, Sherry NA, Jones RM, MacDonald SM, Pulsifer MB, Lavally B, Abrams AN, Huang MS, Marcus KJ, Tarbell NJ.
Long-term toxic effects of proton radiotherapy for paediatric medulloblastoma: a phase 2 single-arm study.
Lancet Oncol. 2016 Mar;17(3):287-98. doi: 10.1016/S1470-2045(15)00167-9. Epub 2016 Jan 30.
Source | Abstract | Full text | Similar articles